Kebede Hussein

发表

Bortezomib therapy in myelofibrosis: a phase II clinical trial

S. Verstovsek, R. Mesa, A. Tefferi, 2008, Leukemia.

Chromosome 1 abnormalities in myeloid malignancies: a literature survey and karyotype–phenotype associations

A. Tefferi, D. Caramazza, R. Ketterling, 2010, European journal of haematology.

International Prognostic Scoring System-independent cytogenetic risk categorization in primary myelofibrosis.

A. Tefferi, A. Pardanani, C. Hanson, 2010, Blood.

Conventional cytogenetics in myelofibrosis: literature review and discussion

A. Tefferi, D. V. Van Dyke, K. Hussein, 2009, European journal of haematology.

Karyotype complements the International Prognostic Scoring System for primary myelofibrosis

R. Mesa, A. Tefferi, T. Lasho, 2009, European journal of haematology.

Peripheral blood cytogenetic studies in myelofibrosis: overall yield and comparison with bone marrow cytogenetic studies.

R. Mesa, A. Tefferi, G. Dewald, 2008, Leukemia research.

Peripheral blood cytogenetic studies in hematological neoplasms: predictors of obtaining metaphases for analysis

A. Tefferi, R. Ketterling, C. Hanson, 2008, European Journal of Haematology.

Prevention of Jarisch-Herxheimer reactions by treatment with antibodies against tumor necrosis factor alpha.

D. Lalloo, D. Fekade, K. Knox, 1996, The New England journal of medicine.

Transfusion‐dependency at presentation and its acquisition in the first year of diagnosis are both equally detrimental for survival in primary myelofibrosis—prognostic relevance is independent of IPSS or karyotype

F. Passamonti, A. Tefferi, A. Pardanani, 2009, American journal of hematology.

JAK2 germline genetic variation affects disease susceptibility in primary myelofibrosis regardless of V617F mutational status: nullizygosity for the JAK2 46/1 haplotype is associated with inferior survival

A. Tefferi, W. Hogan, M. Litzow, 2010, Leukemia.

The Myelofibrosis Symptom Assessment Form (MFSAF): an evidence-based brief inventory to measure quality of life and symptomatic response to treatment in myelofibrosis.

J. Sloan, H. Kantarjian, S. Verstovsek, 2009, Leukemia research.

Cytogenetic correlates of TET2 mutations in 199 patients with myeloproliferative neoplasms

O. Abdel-Wahab, R. Levine, A. Tefferi, 2009, American journal of hematology.

Red blood cell transfusion need at diagnosis adversely affects survival in primary myelofibrosis—increased serum ferritin or transfusion load does not

D. Steensma, R. Mesa, A. Tefferi, 2009, American journal of hematology.

JAK2V617F prevalence and allele burden in non-splanchnic venous thrombosis in the absence of overt myeloproliferative disorder

A. Tefferi, T. Lasho, A. Pardanani, 2007, Leukemia.

5-Azacitidine has limited therapeutic activity in myelofibrosis

S. Verstovsek, R. Mesa, A. Tefferi, 2009, Leukemia.

Deferasirox treatment may be associated with reversible renal Fanconi syndrome

R. Mesa, Wenting Wu, W. Hogan, 2009, American journal of hematology.

Circulating blasts or myeloid precursor cells in peripheral blood can predict success of cytogenetic analysis.

A. Tefferi, C. Hanson, A. Wiktor, 2009, Leukemia research.

Mature survival data for 176 patients younger than 60 years with primary myelofibrosis diagnosed between 1976 and 2005: evidence for survival gains in recent years.

A. Tefferi, A. Pardanani, C. Hanson, 2009, Mayo Clinic proceedings.

Conventional cytogenetics in myelofibrosis: literature review and discussion

A. Tefferi, D. V. Van Dyke, Kebede Hussein, 2009, European journal of haematology.

Phase1/‐2 study of Pomalidomide in myelofibrosis

R. Mesa, Wenting Wu, W. Hogan, 2010, American journal of hematology.

Day 14 bone marrow biopsy in predicting complete remission and survival in acute myeloid leukemia

P. Gupta, D. Weisdorf, B. Jahagirdar, 2008, American journal of hematology.

JAK2V617F mutation screening as part of the hypercoagulable work-up in the absence of splanchnic venous thrombosis or overt myeloproliferative neoplasm: assessment of value in a series of 664 consecutive patients.

A. Tefferi, T. Lasho, A. Pardanani, 2008, Mayo Clinic proceedings.